St. Jude launches PAD device in India; InVivo wins FDA nod for U.S. trial;

@FierceMedDev: St. Jude faces fresh crop of Riata suits. Story | Follow @FierceMedDev

@MarkHFierce: David vs Goliath (J&J). David won. And then he lost on appeal. More | Follow @MarkHFierce

 @DamianFierce: Cancer Genetics is finally going public--at about 14% of its preliminary IPO pricing. News | Follow @DamianFierce

> Foundation Medicine has signed on to handle companion diagnostics for Agios Pharmaceuticals' cancer therapies. Article

> InVivo Therapeutics ($NVIV), won the FDA's blessing to kick off human studies in the U.S. of its biopolymer scaffold to treat spinal cord injuries. News

> St. Jude Medical ($STJ) has launched its PAD-treating Ilumien PCI device in India. Story

> PeriGen, maker of fetal surveillance devices, has raised $6.4 million in venture cash to boost its market adoption. More

> Terumo inked a multi-year distribution agreement with Nonin Medical to market that company's Equanox Model 7600 Regional Oximetry System to cardiovascular hospitals in the U.S. Item

> CryoLife won 510(k) clearance for a next-generation kidney dialysis device. Story

> Senate Republicans were hoping their House counterparts would pass a standalone medical device tax repeal bill, but Roll Call reports representatives would prefer to roll the effort into broad tax reform legislation. Report

Biotech News

@FierceBiotech: In case you missed it yesterday: Fierce's 10 top biotech billionaires. Special report | Follow @FierceBiotech

@JohnCFierce: Receptos--experienced team with CEO Faheem Hasnain (Facet)--files for IPO. S-1 | Follow @JohnCFierce.

@RyanMFierce: Looks like BMY and VRTX have struck another let's-see-what-happens deal in Hep C. Phase II only pact for now. Release | Follow @RyanMFierce

> Sarepta sustains high hopes for DMD drug eteplirsen with more PhII data. Article

> AstraZeneca reports hit-and-miss PhIII for arthritis pill. Report

> Astellas, Ambrx seal $300M cancer ADC deal. News

Pharma News

@FiercePharma: India's top court rebuffs Merck, lets generic Januvia roll despite patent, at least for now. More | Follow @FiercePharma

@EricPFierce: FDA has no comment on judge's ruling to make Teva's Plan B available OTC to adolescents. Story | Follow @EricPFierce

> Roche's Tamiflu, GSK's Relenza work against new bird flu strain. Item

> Pfizer needs consumer unit as pipeline in prescription to OTC trend. Article

> IMS sees little drug spending impact from shift to managed Medicaid plans. Report